Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2060]

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor...

Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation ( Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany )

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue...

Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA)...

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia ( Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy )

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL...

Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL ( Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA )

Selinexor plus ruxolitinib improves spleen response and survival in Janus...

Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis ( Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK )

Fatigue in adult ITP is common despite adequate platelet counts and minimal...

Prof David Kuter - Harvard Medical School, Boston, USA

Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding ( Prof David Kuter - Harvard Medical School, Boston, USA )

Surovatamig plus rituximab induces high complete response rates in previously...

Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma ( Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia )

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in...

Dr Frederick Chen - Barts Health NHS Trust, London, UK

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )

CLL TIM risk model predicts infection and treatment need in newly diagnosed...

Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark

CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia ( Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark )

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )

Epcoritamab induces deep and durable responses in chemotherapy-ineligible...

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse...

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell...

Prof Marek Trněný - Charles University, Prague, Czechia

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas ( Prof Marek Trněný - Charles University, Prague, Czechia )

More from ecancer